Press Release
Feb 15, 2024
Investing in the Next Frontier of Healthcare: Navigating Opportunities in In Vivo Gene Editing Technologies
YolTech Therapeutics operates as a gene editing company at the forefront of medical innovation
Share
LATESTNEWS
-
YolTech Therapeutics Receives FDA Clearance to Initiate Phase 2/3 Study of In Vivo Gene-Editing Therapy YOLT-202 in Alpha-1 Antitrypsin Deficiency (AATD)
Mar 13, 2026
-
YolTech Therapeutics Reports 24-Week Clinical Data for YOLT-101 in Nature Medicine
Mar 04, 2026
-
YolTech Therapeutics Announces Positive Interim Data on YOLT-202 for the Treatment of Alpha-1 Antitrypsin Deficiency
Feb 19, 2026
